Phase 2 Study of HB0017 Injection to Treat Moderate to Severe Plaque Psoriasis Using Different Dose Schedules

What this Trial Is About

Researchers are evaluating the effectiveness, safety, and immune response of HB0017 injection given in different dosing schedules for adults with moderate to severe plaque psoriasis. This randomized, double-blind phase 2 trial focuses on patients who have had chronic plaque psoriasis for at least six months and meet specific severity scores. The study aims to better understand how various doses and timing of HB0017 impact psoriasis symptoms. Participants will be assigned randomly to one of three groups receiving HB0017 at different doses and schedules a higher dose with a longer dosing interval 300mg every 12 weeks, a higher dose with a shorter dosing interval 300mg every 8 weeks, or a lower dose with the shortest dosing interval 150mg every 4 weeks. The trial is designed to compare these regimens to assess their effects on psoriasis severity and maintenance of response. During the study, participants will be monitored closely with assessments of skin improvement using the Psoriasis Area Severity Index PASI and Static Physician Global Assessment sPGA at week 12, with follow-up evaluations up to week 48 to track ongoing response. Safety and immune reactions will also be observed throughout. The total study duration spans from initial treatment to long-term follow-up, ensuring detailed evaluation of both short- and longer-term effects of the HB0017 regimens.

A Phase 2 Study of HB0017 in Psoriasis Patients